Navigation Links
Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
Date:5/24/2013

BEIJING, May 24, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility. The GMP certificate covers Sinovac Beijing's vaccines commercialized in China and approved for stockpiling, inclusive of hepatitis A vaccine (human diploid cell), inactivated; hepatitis A and B combined vaccine; influenza vaccine (split virion), inactivated; pandemic influenza vaccine (inactivated, adjuvanted); pandemic influenza vaccine (split virion, adjuvanted); H1N1 influenza A vaccine (Split Virion, inactivated) The GMP certificate is valid for five years starting from April 17, 2013.

New GMP standards were implemented in China by the CFDA in March 2011. These new standards are in line with international standards. According to the notice for the implementation of new GMP guidelines (2010 version) issued by CFDA in February 2011, all China-based vaccine manufacturers are required to pass the new GMP certification by the end of 2013.

In December 2012, the CFDA conducted a on-site inspection on Sinovac Beijing's production plants in Haidian district and the new filling and packaging line in Changping district according to the Good Manufacturing Practice for Drugs (2010 Revision), the new GMP guidelines. The CFDA granted Sinovac the GMP Certification in April 2013 following the March 2013 public notification period.

Dr. Weidong YIN, Chairman,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
4. Sinovac Schedules 2012 Annual Meeting of Shareholders
5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 /PRNewswire/ ... industry. Because of its leading role in educating thought ... the functions that can heavily influence how well a ... to a new study from research and consulting leader ... Medical Affairs leaders need to focus on are early ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... Progress in Advancing Second-Generation ... CCR9 Drug towards ... announced the completion of enrollment of 436 patients in the,company,s ... a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in patients with ...
... DIEGO, June 12 Vical Incorporated,(Nasdaq: VICL ... of cash payments,and equity investments from AnGes MG, ... funding of the company,s ongoing,Allovectin-7(R) Phase 3 metastatic ... equity investments, Vical has received $15.3 million to ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4
(Date:7/3/2015)... ... 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 (a ... Westin Galleria Dallas. , Designed to take participants from the basic training and fundamentals ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness ... where they provide members of the Red Deer community with free fitness training and ... fitness training, games, food, events and entertainment raised thousands of charity dollars and ended ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by JAMA Internal ... outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity in the ... now," Becic said. "We must understand the magnitude of this discovery. For that reason, ...
(Date:7/2/2015)... ... ... Achebe realized that the gift of poetry was fully in him, as beautiful phrases riddled ... three years later he was publishing an entire book of poetry. He knew there was ... always believed that the best way to lift yourself up, is in the effort of ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... medical issues as adults, analysis finds , MONDAY, May ... cancer survivors finds they are more likely to suffer ... , Emily Dowling, of the U.S. National Cancer Institute, ... the National Health Interview Survey from the last few ...
... ,too much too soon, but study finds no impact ... -- Some American parents are choosing to space out ... infants are getting too many shots too soon, potentially ... has been especially persistent when it comes to autism, ...
... ... , ... -- David Jayne of Rex, Georgia was diagnosed with Lou Gehrig,s disease at age 27. ... atrophy, leaving him unable to eat, breathe or move on his own. , , ,Though ...
... ... for company branding and lead geneneration programs., , ... (PRWEB) May 21, 2010 -- Yeremian Associates, Marketing Tips cover tactics such as ... a low-cost, effective and measurable strategy Sales & Marketing: Tips on Exhibiting Success ...
... Knowledge regarding environmental factors influencing the risk of ... this area. In particular, the roles of smoking and ... this month in the Journal of Alzheimer,s Disease ... the risk of Alzheimer,s disease, particularly in women who ...
... ... before committing suicide. This type of bullying behavior is becoming a staple of youth culture. ... ... at school for months before committing suicide. In a nation where students are being ...
Cached Medicine News:Health News:No Benefit Seen in Delaying Infant Vaccinations 2Health News:No Benefit Seen in Delaying Infant Vaccinations 3Health News:Yeremian Associates, a Full-Service Marketing/Advertising/Public Relations Agency, Offers Marketing Tips for Business-to-Business Solutions 2Health News:Bullying Assembly Uses Comedy to Reach Students 2Health News:Bullying Assembly Uses Comedy to Reach Students 3
... Used for stone manipulation ... urinary tract. Enhanced wire ... dilation in the ureter. ... easy, ergonomic one-handed operation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used to provide drainage following open ... are employed to provide enhanced drainage ... provides maximum softness for enhanced patient ... to latex catheters. Supplied sterile in ...
... Reflotron Plus Chemistry Analyzer is an in ... determination of clinical chemistry parameters using Reflotron Test ... photometry and ensures rapid and reliable results while ... a clear LC display and the profile can ...
Medicine Products: